Follicular lymphoma is a very diverse disease, and decisions to treat in the frontline are made based on histology, disease burden and patient symptoms. The general approach should be a ...

Follicular lymphoma is the second most common form ... and it has a five-year survival rate of only 20% for patients in the third line and later. The new use is the third for Kymriah ...

(NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a new collaboration with the Institute for Follicular Lymphoma ...

Roche has secured its first regulatory approval for mosunetuzumab, a first-in-class CD20xCD3 bispecific antibody, as a treatment for patients with follicular lymphoma (FL) in the EU.

Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

Cancer Center's lymphoma specialist, Dr. Palomba, provides an in-depth look at how CAR T-cell therapy is evolving to offer hope for more patients battling hematologic malignancies.

TEM basically mixes genomic and clinical data with AI. This is at the core of their new offerings for precision diagnostics ...

Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non-chemotherapy treatment regimen ...

Although CAR T-cell therapies have been found effective against certain difficult-to-treat malignancies, they are not devoid of safety concerns.

Discover how 18F-FDG PET and PET/CT provide critical diagnostic accuracy for detecting high-grade transformations in chronic ...